AI identifies patient subgroups with distinct drug responses in clinical trial emulation

Researchers have developed a method to optimize clinical trial protocols by using electronic health records to identify heterogeneous treatment effects (HTEs). By emulating the DAPA-HF trial with data from the Mayo Clinic Cloud, they investigated if HTE-guided stratification could reveal distinct patient subgroups responding differently to dapagliflozin. While the overall trial emulation showed no significant survival benefit, the HTE-guided approach identified a subgroup that significantly benefited from dapagliflozin and another subgroup that experienced a harmful association with increased mortality. AI

IMPACT This approach could lead to more personalized medicine by identifying patient subgroups that benefit or are harmed by specific treatments.

RANK_REASON The cluster contains an academic paper detailing a new methodology for clinical trial analysis. [lever_c_demoted from research: ic=1 ai=0.7]

Read on arXiv cs.AI →

• dapagliflozin
• DAPA-HF Investigators and Committees
• HTE-guided stratification
• Mayo Clinic Cloud
• Meta-S learner

• paper
• other

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →